In vivo Studies on Pharmacokinetics, Toxicity and Immunogenicity of Polyelectrolyte Nanocapsules Functionalized with Two Different Polymers: Poly-L-Glutamic Acid or PEG

References

• Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33(10):2373–2387. doi:10.1007/s11095-016-1958-527299311
   PubMed Web of Science ®Google Scholar
• Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–951. doi:10.1038/nbt.333026348965
   PubMed Web of Science ®Google Scholar
• Aleksiichuk V, Omelchuk S, Sokurenko L, Kaminsky R, Kovalchuk O, Chaikovsky Y. The influence of lead nanoparticles on the morpho-functional changes of rat liver during the postexposure period. Diaspro A, ed. Microsc Res Tech. 2018;81(7):781–788. doi:10.1002/jemt.2303629652104
   PubMedGoogle Scholar
• Stueckle TA, Davidson DC, Derk R, et al. Short-term pulmonary toxicity assessment of pre- and post-incinerated organomodified nanoclay in mice. ACS Nano. 2018;12(3):2292–2310. doi:10.1021/acsnano.7b0728129451776
   PubMedGoogle Scholar
• Shin JH, Jeon K, Kim JK, et al. Subacute inhalation toxicity study of synthetic amorphous silica nanoparticles in Sprague-Dawley rats. Inhal Toxicol. 2017;29(12–14):567–576. doi:10.1080/08958378.2018.142666129400116
   PubMed Web of Science ®Google Scholar
• Tiwari R, Singh RD, Khan H, et al. Oral subchronic exposure to silver nanoparticles causes renal damage through apoptotic impairment and necrotic cell death. Nanotoxicology. 2017;11(5):671–686. doi:10.1080/17435390.2017.134387428617070
   PubMed Web of Science ®Google Scholar
• Bahadar H, Maqbool F, Niaz K, Abdollahi M. Toxicity of Nanoparticles and an overview of current experimental models. Iran Biomed J. 2016;20(1):1–11. doi:10.7508/ibj.2016.01.00126286636
   PubMedGoogle Scholar
• Perret P, Bacot S, Gèze A, et al. Biodistribution and preliminary toxicity studies of nanoparticles made of biotransesterified β–cyclodextrins and PEGylated phospholipids. Mater Sci Eng C. 2018;85:7–17. doi:10.1016/J.MSEC.2017.12.017
   PubMed Web of Science ®Google Scholar
• Bulcão RP, de Freitas FA, Dallegrave E, et al. In vivo toxicological evaluation of polymeric nanocapsules after intradermal administration. Eur J Pharm Biopharm. 2014;86(2):167–177. doi:10.1016/J.EJPB.2013.04.00123643792
   PubMed Web of Science ®Google Scholar
• Bojarová P, Tavares MR, Laaf D, et al. Biocompatible glyconanomaterials based on HPMA-copolymer for specific targeting of galectin-3. J Nanobiotechnol. 2018;16(1):73. doi:10.1186/s12951-018-0399-1
   PubMedGoogle Scholar
• Croissant JG, Brinker CJ. Biodegradable silica-based nanoparticles: dissolution kinetics and selective bond cleavage. Enzymes. 2018;43:181–214. doi:10.1016/BS.ENZ.2018.07.00830244807
   PubMedGoogle Scholar
• Shen Y-Q, Zhu Y-J, Yu H-P, Lu B-Q. Biodegradable nanocomposite of glycerol citrate polyester and ultralong hydroxyapatite nanowires with improved mechanical properties and low acidity. J Colloid Interface Sci. 2018;530:9–15. doi:10.1016/j.jcis.2018.06.05929960123
   PubMed Web of Science ®Google Scholar
• Abd Ellah NH, Abouelmagd SA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Expert Opin Drug Deliv. 2017;14(2):201–214. doi:10.1080/17425247.2016.121323827426638
   PubMed Web of Science ®Google Scholar
• Sathyamoorthy N, Dhanaraju MD. Shielding therapeutic drug carriers from the mononuclear phagocyte system: a review. Crit Rev Ther Drug Carrier Syst. 2016;33(6):489–567. doi:10.1615/CritRevTherDrugCarrierSyst.201601230327992308
   PubMed Web of Science ®Google Scholar
• Hu C-MJ, Fang RH, Luk BT, Zhang L. Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nanoscale. 2014;6(1):65–75. doi:10.1039/C3NR05444F24280870
   PubMed Web of Science ®Google Scholar
• Bzowska M, Karabasz A, Szczepanowicz K. Encapsulation of camptothecin into pegylated polyelectrolyte nanocarriers. Colloids Surf A. 2018;557:36–42. doi:10.1016/J.COLSURFA.2018.05.070
   Web of Science ®Google Scholar
• Karabasz A, Bzowska M, Łukasiewicz S, Bereta J, Szczepanowicz K. Cytotoxic activity of paclitaxel incorporated into polyelectrolyte nanocapsules. J Nanop Res. 2014;16(4):2340. doi:10.1007/s11051-014-2340-3
   Google Scholar
• Szczepanowicz K, Bzowska M, Kruk T, Karabasz A, Bereta J, Warszynski P. Pegylated polyelectrolyte nanoparticles containing paclitaxel as a promising candidate for drug carriers for passive targeting. Colloids Surf B Biointerfaces. 2016;143:463–471. doi:10.1016/j.colsurfb.2016.03.06427037784
   PubMed Web of Science ®Google Scholar
• Łukasiewicz S, Szczepanowicz K, Podgórna K, et al. Encapsulation of clozapine in polymeric nanocapsules and its biological effects. Colloids Surf B Biointerfaces. 2016;140:342–352. doi:10.1016/J.COLSURFB.2015.12.04426774571
   PubMed Web of Science ®Google Scholar
• Piotrowski M, Jantas D, Szczepanowicz K, Łukasiewicz S, Lasoń W, Warszyński P. Polyelectrolyte-coated nanocapsules containing undecylenic acid: synthesis, biocompatibility and neuroprotective properties. Colloids Surf B Biointerfaces. 2015;135:8–17. doi:10.1016/j.colsurfb.2015.07.02926231861
   PubMedGoogle Scholar
• Karabasz A, Szczepanowicz K, Cierniak A, Bereta J, Bzowska M. In vitro toxicity studies of biodegradable, polyelectrolyte nanocapsules. Int J Nanomedicine. 2018;13:5159–5172. doi:10.2147/IJN.S16912030233178
   PubMed Web of Science ®Google Scholar
• Hermanson GT. Bioconjugate Techniques. Elsevier Academic Press; 2008.
   Google Scholar
• Szczepanowicz K, Hoel HJ, Szyk-Warszynska L, et al. Formation of biocompatible nanocapsules with emulsion core and pegylated shell by polyelectrolyte multilayer adsorption. Langmuir. 2010;26(15):12592–12597. doi:10.1021/la102061s20604580
   PubMed Web of Science ®Google Scholar
• Lukasiewicz S, Szczepanowicz KP, Blasiak E, Dziedzicka-Wasylewska M. biocompatible polymeric nanoparticles as promising candidates for drug delivery. Langmuir. 2015;31(23):64156425. doi:10.1021/acs.langmuir.5b01226
   Web of Science ®Google Scholar
• Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 2013;42(12):5552. doi:10.1039/c3cs60064e23549679
   PubMed Web of Science ®Google Scholar
• Almeida JPM, Chen AL, Foster A, Drezek R. In vivo biodistribution of nanoparticles. Nanomedicine. 2011;6(5):815–835. doi:10.2217/nnm.11.7921793674
   PubMed Web of Science ®Google Scholar
• Hirsjärvi S, Sancey L, Dufort S, et al. Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting. Int J Pharm. 2013;453:594–600. doi:10.1016/j.ijpharm.2013.05.05723747436
   PubMed Web of Science ®Google Scholar
• Ramasamy T, Haidar ZS, Tran TH, et al. Layer-by-layer assembly of liposomal nanoparticles with PEGylated polyelectrolytes enhances systemic delivery of multiple anticancer drugs. Acta Biomater. 2014;10(12):5116–5127. doi:10.1016/J.ACTBIO.2014.08.02125169256
   PubMed Web of Science ®Google Scholar
• Li S-D HL. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release. 2010;145(3):178–181. doi:10.1016/j.jconrel.2010.03.01620338200
   PubMedGoogle Scholar
• Saxena V, Sadoqi M, Shao J. Polymeric nanoparticulate delivery system for indocyanine green: biodistribution in healthy mice. Int J Pharm. 2006;308(1–2):200–204. doi:10.1016/j.ijpharm.2005.11.00316386861
   PubMedGoogle Scholar
• Garcia GM, Oliveira LT, Pitta I da R, et al. Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation. J Control Release. 2015;209:207–218. doi:10.1016/j.jconrel.2015.04.03325931305
   PubMedGoogle Scholar
• Zhang Y-N, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332–348. doi:10.1016/J.JCONREL.2016.01.02026774224
   PubMed Web of Science ®Google Scholar
• Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine. 2008;3(5):703–717. doi:10.2217/17435889.3.5.70318817471
   PubMed Web of Science ®Google Scholar
• Abellan-Pose R, Rodríguez-Évora M, Vicente S, et al. Biodistribution of radiolabeled polyglutamic acid and PEG-polyglutamic acid nanocapsules. Eur J Pharm Biopharm. 2017;112:155–163. doi:10.1016/J.EJPB.2016.11.01527865858
   PubMed Web of Science ®Google Scholar
• Gonzalo T, Lollo G, Garcia-Fuentes M, et al. A new potential nano-oncological therapy based on polyamino acid nanocapsules. J Control Release. 2013;169(1–2):10–16. doi:10.1016/J.JCONREL.2013.03.03723591661
   PubMedGoogle Scholar
• Wm A, Dw N, Ko O, Ngugi M, Enm N. Biochemical markers of in vivo hepatotoxicity. J Clin Toxicol. 2016;6(2):297–305. doi:10.4172/2161-0495.1000297
   Google Scholar
• Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxicity – an overview for applied toxicology. AAPS J. 2011;13(4):615–631. doi:10.1208/s12248-011-9301-x21969220
   PubMed Web of Science ®Google Scholar
• Hong S, Leroueil PR, Janus EK, et al. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem. 2006;17(3):728–734. doi:10.1021/bc060077y16704211
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Szebeni J, Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42(6):463–478.14559067
   PubMed Web of Science ®Google Scholar
• Ulbricht J, Jordan R, Luxenhofer R. On the biodegradability of polyethylene glycol, polypeptoids and poly(2-oxazoline)s. Biomaterials. 2014;35(17):4848–4861. doi:10.1016/J.BIOMATERIALS.2014.02.02924651032
   PubMedGoogle Scholar
• Aragao-Santiago L, Hillaireau H, Grabowski N, et al. Compared in vivo toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles. Nanotoxicology. 2016;10(3):292–302. doi:10.3109/17435390.2015.105490826573338
   PubMed Web of Science ®Google Scholar
• Roberts RA, Shen T, Allen IC, Hasan W, DeSimone JM, Ting JPY. Analysis of the murine immune response to pulmonary delivery of precisely fabricated nano- and microscale particles. Hussain S, ed. PLoS One. 2013;8(4):e62115. doi:10.1371/journal.pone.006211523593509
   PubMed Web of Science ®Google Scholar
• Neun B, Barenholz Y, Szebeni J, Dobrovolskaia M. Understanding the role of anti-PEG antibodies in the complement activation by doxil in vitro. Molecules. 2018;23(7):1700. doi:10.3390/molecules23071700
   PubMed Web of Science ®Google Scholar
• Cheng T-L, Wu P-Y, Wu M-F, Chern J-W, Roffler SR. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM. Bioconjug Chem. 1999;10(3):520–528. doi:10.1021/BC980143Z10346886
   PubMed Web of Science ®Google Scholar
• Ichihara M, Shimizu T, Imoto A, et al. Anti-PEG IgM response against PEGylated Liposomes in mice and rats. Pharmaceutics. 2010;3(1):1–11. doi:10.3390/pharmaceutics301000124310423
   PubMedGoogle Scholar
• Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Dahlqvist SR. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheumatism. 2010;62(2):383–391. doi:10.1002/art.2718620112361
   PubMedGoogle Scholar
• Gui S, Zhang Z, Zheng L, et al. Molecular mechanism of kidney injury of mice caused by exposure to titanium dioxide nanoparticles. J Hazard Mater. 2011;195:365–370. doi:10.1016/j.jhazmat.2011.08.05521907489
   PubMed Web of Science ®Google Scholar
• Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med. 2008;205(10):2281–2294. doi:10.1084/jem.2007111918779348
   PubMed Web of Science ®Google Scholar